Maxim Group initiated coverage on shares of Citius Oncology (NASDAQ:CTOR – Free Report) in a research note released on Wednesday, MarketBeat reports. The brokerage issued a buy rating and a $3.00 target price on the stock.
Citius Oncology Stock Performance
NASDAQ CTOR opened at $0.94 on Wednesday. The stock’s 50 day simple moving average is $1.19. Citius Oncology has a 12-month low of $0.85 and a 12-month high of $49.00.
About Citius Oncology
See Also
- Five stocks we like better than Citius Oncology
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- How to Calculate Options Profits
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Pros And Cons Of Monthly Dividend Stocks
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Citius Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
